Author/Editor		Šabovič, M
Title		Vloga rekombinantnih zdravil v zdravljenju kardiovaskularnih bolezni
Translated title		The role of recombinant drugs in the treatment of cardiovascular diseases
Type		članek
Source		Farm Vestn
Vol. and No.		Letnik 47, št. Suppl
Publication year		1996
Volume		str. 157-62
Language		slo
Abstract		Recombinant gene technology has influenced the development of cardiovascular drugs. Recombinant tissue-type plasminogen activator (rt-PA) has already been approved for clinical use. Its main indications is fibrinolytic treatment of acute myocardial infarction. In comparison to streptokinase, which is the standard thrombolytic agent, rt-PA is slightly, but significantly, more effective. Unfortunately, it is also much more expensive. It is mainly used in the United States, whereas in Slovenia it is not licensed. In the United States and a few European coutries Abciximab (monoclonal antibodies againts platelet receptors GPIIb/IIIa) has been approved for the prevention of reocclusion after PTCA. Other recombinant fibrinolytic, antiplatelet and anticoagulant drugs are being tested in clinical trials. It seems likely that some of them will replace the existing antithrombotic drugs.
Descriptors		CARDIOVASCULAR DISEASES RECOMBINANT PROTEINS FIBRINOLYTIC AGENTS ALTEPLASE ANTICOAGULANTS